Trial Profile
Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 20 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 16 May 2022 Planned End Date changed from 30 Sep 2022 to 31 Dec 2023.
- 16 May 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Dec 2023.